|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/14 | |
| A61K 31/4745 | |||
| A61P 35/00 | |||
| A61P 37/00 | |||
| A61P 29/00 |
| (11) | Number of the document | 3169687 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15821295.1 |
| Date of filing the European patent application | 2015-07-11 | |
| (97) | Date of publication of the European application | 2017-05-24 |
| (45) | Date of publication and mention of the grant of the patent | 2019-01-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/040076 |
| Date | 2015-07-11 |
| (87) | Number | WO 2016/010869 |
| Date | 2016-01-21 |
| (30) | Number | Date | Country code |
| 201462024192 P | 2014-07-14 | US |
| (72) |
CHEN, Guoqing, Paul, US
YAN, Changren, US
REALE, Michael, US
CHEN, Monica, US
|
| (73) |
ADVENCHEN PHARMACEUTICALS, NANJING LTD.,
Room 302, Block A Pharmaceutical & Biology Incubator Building Entrepreneurship Center Nanjing New & High Tech Zone, Nanjing, Jiangsu 210061,
CN
|
| (54) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
| FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |